# EDGAR Filing Document

**Accession Number:** 0001425205
**File Stem:** 0001104659-25-066983
**Filing Date:** 2025-7
**Character Count:** 6246
**Document Hash:** f83e3be431b700b6c259f39b76d60827
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-066983.hdr.sgml**: 20250710

**ACCESSION NUMBER**: 0001104659-25-066983

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250710

**DATE AS OF CHANGE**: 20250710

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Rosinack Matthew W.
- **CENTRAL INDEX KEY:** 0001824797

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36860
- **FILM NUMBER:** 251116379

**MAIL ADDRESS:**
- **STREET 1:** C/O BERKELEY LIGHTS, INC.
- **STREET 2:** 5858 HORTON STREET, SUITE 320
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IOVANCE BIOTHERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001425205
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 753254381
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD
- **STREET 2:** 4TH FLOOR
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070
- **BUSINESS PHONE:** 6502607120

**MAIL ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD
- **STREET 2:** 4TH FLOOR
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lion Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20131015

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Genesis Biopharma, Inc
- **DATE OF NAME CHANGE:** 20100319

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FREIGHT MANAGEMENT CORP
- **DATE OF NAME CHANGE:** 20080128

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Rosinack Matthew W.<br><sub>(Last) (First) (Middle)</sub><br>C/O IOVANCE BIOTHERAPEUTICS, INC.<br>825 INDUSTRIAL ROAD, SUITE 100<br><sub>(Street)</sub><br>SAN CARLOS, CA 94070<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-06-30 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_SVP, Finance (Int. PFO & PAO)_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 89129<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to Buy) | <sup>(2)</sup> | 2031-09-27 | Common Stock | 75000 | $25.30 | D |  |
| Restricted Stock Units | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 11721 | <sup>(6)</sup> | D |  |
| Restricted Stock Units | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 38287 | <sup>(6)</sup> | D |  |
| Restricted Stock Units | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 59060 | <sup>(6)</sup> | D |  |

---

### Footnotes:

(1) Includes 9,089 shares of Iovance Biotherapeutics, Inc.'s (the "Issuer") common stock purchased under the Issuer's 2020 Employee Stock Purchase Plan.

(2) The stock option was granted on September 27, 2021. The shares underlying this option are fully vested.

(3) The restricted stock units ("RSUs") were granted on March 2, 2023. One-third of the RSUs vested on March 2, 2024. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter.

(4) The RSUs were granted on March 1, 2024. One-third of the RSUs vested on March 1, 2025. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter.

(5) The RSUs were granted on March 5, 2025. One-third of the RSUs will vest on March 5, 2026. The remaining RSUs will vest in eight equal quarterly installments thereafter.

(6) Each RSU represents a contingent right to receive one share of the Issuer's common stock.

**Remarks:**
On June 30, 2025, Matthew William Rosinack was appointed as the Issuer's interim Principal Financial Officer and Principal Accounting Officer. Mr. Rosinack has served as the Issuer's Senior Vice President, Finance since September 2021.

**Signature:** /s/ Matthew William Rosinack  
**Date:** 2025-07-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**